Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin in Immune Thrombocytopenia Patients With Cardiovascular Disease
NCT04912505Phase 2Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aspirin in immune thrombocytopenia (ITP), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Thromboxane B2 at 24 hours. Started Jan 2023; status: completed.
02
Drugs
aspirin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04912505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04912505.